Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 10Gastrointestinal 4Lymphoid 2CNS 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Head and Neck Neoplasms 174Squamous Cell Carcinoma of Head and Neck 147Nasopharyngeal Carcinoma 126Oropharyngeal Neoplasms 25Thyroid Neoplasms 23Nasopharyngeal Neoplasms 21Mouth Neoplasms 21Carcinoma, Squamous Cell 19Laryngeal Neoplasms 17Neoplasms 15Radiation Injuries 13Hypopharyngeal Neoplasms 13Salivary Gland Neoplasms 11Carcinoma 11Stomatitis 10Recurrence 10Laryngeal Diseases 10Tongue Neoplasms 9Mucositis 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pain 7Neoplasm Metastasis 7Esthesioneuroblastoma, Olfactory 7Xerostomia 6Uterine Cervical Neoplasms 6Differentiated Thyroid Cancer 6Breast Neoplasms 6Thyroid Cancer, Papillary 5Parathyroid Neoplasms 4Melanoma 4

Interventions

Megestrol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cachexia × Head & Neck × Clear all
NCT00006799 2021-09-09

Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer

Wake Forest University Health Sciences

Phase 3 Completed
13 enrolled
CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anorexia, Cachexia, Head and Neck Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡